Newsfeeds - Spark Newswire

7 minute read

Meet The Top 12 CEOs In The Psychedelics Industry

Today, 12:59 PM

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.

ATAI

1 minute read

ATAI Life Sciences Shares See Volume; Traders Circulate TipRanks Report Titled ‘Billionaire Israel Englander Pours Money Into 3 “Strong Buy” Stocks’ Mentioning Stock

By Benzinga Newsdesk

Today, 12:59 PM

https://www.tipranks.com/news/article/billionaire-israel-englander-pours-money-into-3-strong-buy-stocks/

ATAI

1 minute read

Analyst Ratings

What 10 Analyst Ratings Have To Say About ATAI Life Sciences

By Benzinga Insights

Today, 12:59 PM

Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:ATAI) within the last quarter:

ATAI

2 minute read

Analyst Ratings

Where ATAI Life Sciences Stands With Analysts

By Benzinga Insights

Today, 12:59 PM

ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

ATAI

1 minute read

Analyst Ratings

What 9 Analyst Ratings Have To Say About ATAI Life Sciences

By Benzinga Insights

Today, 12:59 PM

ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

ATAI

1 minute read

Argus Research Maintains Buy on ATAI Life Sciences, Raises Price Target to $27

By Benzinga Newsdesk

Today, 12:59 PM

Argus Research analyst Nathan Weinstein maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and raises the price target from $26 to $27.

ATAI

1 minute read

Aegis Capital Maintains Buy on ATAI Life Sciences, Raises Price Target to $27

By Benzinga Newsdesk

Today, 12:59 PM

Aegis Capital analyst Nathan Weinstein maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and raises the price target from $26 to $27.

ATAI

8 minute read

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

By Shanthi Rexaline

Today, 12:59 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)

ABSI

14 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 12:59 PM

On Monday morning, 207 companies hit new 52-week lows.

ACAD

4 minute read

Psyched: Atai Launches ‘Salvia Divinorum’ Subsidiary, Mindset, Psilera and Wesana’s Preclinical Trials, Origin Raises $5M

By Natan Ponieman

Today, 12:59 PM

Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: ATAI) announced the launch of a new subsidiary that will research Salvinorin A, the active compound in salvia divinorum, a hallucinogenic herb native to Central America.

ATAI